Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Ruby Khatun Khatun
    Ruby Khatun Khatun
      • Home
      • Ruby Khatun Khatun

      Articles By : Ruby Khatun Khatun

      Orchid Pharma: Lenders reject resolution plan, Company to move to Liquidation

      Orchid Pharma: Lenders reject resolution plan, Company to move to Liquidation

      Ruby Khatun Khatun16 May 2018 12:52 PM IST
      MUMBAI: The resolution plan of the bankrupt Orchid Pharma has been rejected by the lenders of the company that might drive the firm towards...
      Bankrupt Orchid Pharma Rejects Only Bid for being too low

      Bankrupt Orchid Pharma Rejects Only Bid for being too low

      Ruby Khatun Khatun24 April 2018 5:21 PM IST
      New Delhi: Orchid pharma has invited a fresh bidding after the company has found the only eligible bid for takeover of the company to be low.The...
      Glenmark Pharma to begin phase 2b clinical trial of atopic dermatitis drug

      Glenmark Pharma to begin phase 2b clinical trial of atopic dermatitis drug

      Ruby Khatun Khatun18 April 2018 10:30 AM IST
      New Delhi: Drug major Glenmark Pharmaceuticals announced the initiation of phase 2b clinical trial of GBR 830, a novel investigational treatment for...
      Panacea Biotech, Serum Institute collaborates on six-in-one vaccine

      Panacea Biotech, Serum Institute collaborates on six-in-one vaccine

      Ruby Khatun Khatun20 Jan 2018 11:48 AM IST
      New Delhi: Panacea Biotec has signed two long-term agreements with Serum Institute of India (SII) and its wholly-owned subsidiary to manufacture and...
      Impact of GST on Medicines, Medical Devices, Check out the details

      Impact of GST on Medicines, Medical Devices, Check out the details

      Ruby Khatun Khatun24 May 2017 12:26 PM IST
      The government said on Monday the goods and services tax (GST), scheduled to be rolled out from July 1, was set to benefit consumers, as the tax...
      FDA approves first drug to specifically treat giant cell arteritis

      FDA approves first drug to specifically treat giant cell arteritis

      Ruby Khatun Khatun24 May 2017 10:07 AM IST
      The U.S. Food and Drug Administration expanded the approved use of subcutaneous Actemra (tocilizumab) to treat adults with giant cell arteritis. This...
      Columbia Asia hires Dr Kelvin Loh as CEO to navigate its next phase of growth

      Columbia Asia hires Dr Kelvin Loh as CEO to navigate its next phase of growth

      Ruby Khatun Khatun24 May 2017 9:05 AM IST
      Delhi: Columbia Asia, one of the fastest-growing healthcare companies in Asia, has appointed Dr. Kelvin Loh to serve as CEO, effective July 1.Dr. Loh...
      Severe asthma drug shows AstraZeneca promise beyond cancer

      Severe asthma drug shows AstraZeneca promise beyond cancer

      Ruby Khatun Khatun24 May 2017 9:04 AM IST
      LONDON: AstraZeneca's experimental injection for severe asthma cut substantially the need for patients to take problematic oral steroids drugs in a...
      Zydus Cadila gets USFDA nod for antihistamine drug

      Zydus Cadila gets USFDA nod for antihistamine drug

      Ruby Khatun Khatun24 May 2017 9:04 AM IST
      New Delhi: Drug firm Zydus Cadila said it has received approval from the US health regulator to market antihistamine Cyproheptadine Hydrochloride...
      Gujrat Based Shalby Hospitals eyes IPO, filed draft herring prospectus with SEBI

      Gujrat Based Shalby Hospitals eyes IPO, filed draft herring prospectus with SEBI

      Ruby Khatun Khatun23 May 2017 1:49 PM IST
      Gujrat: The Ahmedabad based Super-Specialty hospital chain, Shalby Hospitals is soon aiming towards an Initial Public Offer (IPO) for listing its...
      DSM Sinochem Pharmaceuticals Wins Indian Patent Infringement Case

      DSM Sinochem Pharmaceuticals Wins Indian Patent Infringement Case

      Ruby Khatun Khatun23 May 2017 1:27 PM IST
      SINGAPORE: DSM Sinochem Pharmaceuticals (DSP), the global leader in production and commercialization of sustainable, enzymatic antibiotics, next...
      Regeneron, Sanofi rheumatoid arthritis drug wins USFDA approval

      Regeneron, Sanofi rheumatoid arthritis drug wins USFDA approval

      Ruby Khatun Khatun23 May 2017 1:23 PM IST
      The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals and Sanofi's biotech drug for adults with moderate to severe rheumatoid...
      Next

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok